Patents Assigned to ESSA Pharma, Inc.
  • Patent number: 11814357
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: November 14, 2023
    Assignee: ESSA Pharma Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • Patent number: 11518747
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: December 6, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • Patent number: 11485713
    Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 1, 2022
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
  • Patent number: 11358938
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: June 14, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • Patent number: 11242324
    Abstract: The present invention relates to a crystalline form of Compound I, a salt, a solvate, or a solvate salt thereof or an amorphous form of Compound I, a salt, a solvate, or a solvate salt thereof. The present invention also provides compositions comprising the crystalline form and/or the amorphous form, therapeutic uses of the crystalline forms and/or the amorphous forms, and the compositions thereof.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: February 8, 2022
    Assignee: ESSA Pharma, Inc.
    Inventors: Han-Jie Zhou, Peter Virsik
  • Patent number: 11059795
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: July 13, 2021
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar